BR112014030279A2 - métodos para tratamento de neutropenia usando agonistas retinóide - Google Patents

métodos para tratamento de neutropenia usando agonistas retinóide

Info

Publication number
BR112014030279A2
BR112014030279A2 BR112014030279A BR112014030279A BR112014030279A2 BR 112014030279 A2 BR112014030279 A2 BR 112014030279A2 BR 112014030279 A BR112014030279 A BR 112014030279A BR 112014030279 A BR112014030279 A BR 112014030279A BR 112014030279 A2 BR112014030279 A2 BR 112014030279A2
Authority
BR
Brazil
Prior art keywords
neutropenia
methods
treatment
retinoid agonists
treating
Prior art date
Application number
BR112014030279A
Other languages
English (en)
Inventor
Wu Lingtao
Original Assignee
Los Angeles Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Los Angeles Childrens Hospital filed Critical Los Angeles Childrens Hospital
Publication of BR112014030279A2 publication Critical patent/BR112014030279A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

resumo da patente de invenção para: “métodos para tratamento de neutropenia usando agonistas retinóide” a invenção fornece métodos para tratar a neutropenia em um indivíduo que necessita deste compreendendo o fornecimento de uma composição que compreende um agonista retinóide e administração de uma quantidade eficaz da composição ao indivíduo para tratar a neutropenia, tratando, desta forma, a neutropenia do indivíduo em necessidade deste.
BR112014030279A 2012-06-07 2013-06-07 métodos para tratamento de neutropenia usando agonistas retinóide BR112014030279A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261656815P 2012-06-07 2012-06-07
PCT/US2013/044828 WO2013185105A1 (en) 2012-06-07 2013-06-07 Methods for treating neutropenia using retinoid agonists

Publications (1)

Publication Number Publication Date
BR112014030279A2 true BR112014030279A2 (pt) 2017-09-12

Family

ID=49712715

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014030279A BR112014030279A2 (pt) 2012-06-07 2013-06-07 métodos para tratamento de neutropenia usando agonistas retinóide

Country Status (14)

Country Link
US (1) US11116738B2 (pt)
EP (1) EP2858636B1 (pt)
JP (1) JP6295249B2 (pt)
KR (1) KR102083046B1 (pt)
CN (1) CN104519879B (pt)
AU (1) AU2013270674B2 (pt)
BR (1) BR112014030279A2 (pt)
CA (1) CA2874850A1 (pt)
ES (1) ES2691493T3 (pt)
HK (1) HK1208630A1 (pt)
MX (1) MX365321B (pt)
NZ (1) NZ702415A (pt)
RU (1) RU2650962C2 (pt)
WO (1) WO2013185105A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX365321B (es) 2012-06-07 2019-05-29 Los Angeles Childrens Hospital Métodos para el tratamiento de neutropenia mediante agonistas retinoides.
US20160000674A1 (en) 2013-03-15 2016-01-07 Avisenna Cosmetics, Llc Topical compositions for reducing the effects of aging
WO2015126989A1 (en) * 2014-02-18 2015-08-27 Children's Hospital Los Angeles Compositions and methods for treating neutropenia
EP3277272B1 (en) 2015-03-31 2021-08-04 Syros Pharmaceuticals, Inc. Methods of stratifying patients for treatment with retinoic acid receptor-agonists
US9868994B2 (en) 2016-04-08 2018-01-16 Syros Pharmaceuticals, Inc. Methods of stratifying patients for treatment with retinoic acid receptor-α agonists
WO2018067946A1 (en) * 2016-10-06 2018-04-12 Syros Pharmaceuticals, Inc. Methods of treating patients with a retinoic acid receptor-alpha agonist and an anti-cd38 antibody
SG11202006376WA (en) * 2018-01-26 2020-07-29 Agency Science Tech & Res Neutrophil subtypes
CN113969261B (zh) * 2020-07-06 2024-04-09 苏州市立医院(北区) 三步法快速测定中性粒细胞趋化的方法
US20220378727A1 (en) * 2021-05-14 2022-12-01 The University Of Hong Kong Dry powder formulations of tamibarotene for pulmonary and intranasal delivery

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5691196A (en) * 1992-12-31 1997-11-25 American Cyanamid Company Recombinant nucleic acid containing a response element
US5965606A (en) 1995-12-29 1999-10-12 Allergan Sales, Inc. Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity
JP2001506998A (ja) * 1996-12-19 2001-05-29 アメリカン・サイアナミド・カンパニー 好中球減少症の治療または抑制方法
WO2002020766A2 (en) 2000-09-08 2002-03-14 Massachusetts Institute Of Technology G-csf analog compositions and methods
US7119061B2 (en) 2002-11-18 2006-10-10 Vicuron Pharmaceuticals, Inc. Dalbavancin compositions for treatment of bacterial infections
US20070172447A1 (en) 2003-05-16 2007-07-26 Kazuhiro Sakurada Agent for preventing and/or treating tissue disruption-accompanied diseases
EP1621191A1 (en) * 2004-07-29 2006-02-01 Werner Bollag Treatment of inflammatory diseases by RXR Antagonists
CN101094684A (zh) * 2004-08-13 2007-12-26 阿诺麦德股份有限公司 用趋化因子的组合活化祖细胞/干细胞
BRPI0517128A (pt) 2004-12-02 2008-09-30 Venus Remedies Ltd composições de combate à resistência a antibióticos, métodos de tratamento e processos de preparação de composição
US20090111786A1 (en) * 2004-12-03 2009-04-30 Glass Christopher K Compounds that Prevent Macrophage Apoptosis and Uses Thereof
EP2026778B1 (en) * 2006-05-16 2018-11-14 Io Therapeutics, LLC Rar antagonist or inverse agonist for use in the treatment of chemotherapy and/or radiation therapy side effects
CN101641091B (zh) * 2007-03-30 2012-09-19 Tmrc株式会社 他米巴罗汀胶囊剂
WO2009070844A1 (en) * 2007-12-06 2009-06-11 Csl Limited Method of inhibition of leukemic stem cells
EP2334814A4 (en) 2008-09-05 2012-04-25 Solulink Biosciences Inc METHODS AND COMPOSITIONS FOR DIRECT DETECTION OF DNA INJURIES
CN102612371B (zh) 2009-10-19 2014-03-19 莱拉营养食品有限公司 含有多聚乙酰的提取物，分馏物和混合物及它们的应用
RU2446173C1 (ru) 2010-08-13 2012-03-27 Зао "Биокад" Новый функционально активный, высокоочищенный стабильный конъюгат гранулоцитарного колониестимулирующего фактора (г-ксф) с полиэтиленгликолем с пролонгированным биологическим действием, пригодный для медицинского применения, и иммунобиологическое средство на его основе
CN102380090A (zh) 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 G-csf二聚体在治疗嗜中性粒细胞减少症中的应用
CA2826386C (en) 2011-02-08 2020-04-28 Cellular Dynamics International, Inc. Hematopoietic precursor cell production by programming
AU2013259624B2 (en) * 2012-05-08 2017-10-19 Lycera Corporation Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease
MX365321B (es) 2012-06-07 2019-05-29 Los Angeles Childrens Hospital Métodos para el tratamiento de neutropenia mediante agonistas retinoides.
DE102012011766B3 (de) 2012-06-15 2013-12-19 Voith Patent Gmbh Getriebeeinheit
CN110946993A (zh) 2014-01-03 2020-04-03 上海泽生科技开发股份有限公司 纽兰格林制剂的配方
WO2015126989A1 (en) 2014-02-18 2015-08-27 Children's Hospital Los Angeles Compositions and methods for treating neutropenia

Also Published As

Publication number Publication date
AU2013270674B2 (en) 2017-12-07
JP2015523346A (ja) 2015-08-13
WO2013185105A1 (en) 2013-12-12
HK1208630A1 (en) 2016-03-11
EP2858636A1 (en) 2015-04-15
CA2874850A1 (en) 2013-12-12
KR102083046B1 (ko) 2020-02-28
NZ702415A (en) 2016-04-29
JP6295249B2 (ja) 2018-03-14
EP2858636A4 (en) 2016-06-01
RU2014153988A (ru) 2016-07-27
CN104519879B (zh) 2018-10-02
AU2013270674A1 (en) 2014-12-18
US20150164836A1 (en) 2015-06-18
EP2858636B1 (en) 2018-09-05
ES2691493T3 (es) 2018-11-27
US11116738B2 (en) 2021-09-14
MX2014014930A (es) 2015-07-06
MX365321B (es) 2019-05-29
RU2650962C2 (ru) 2018-04-18
CN104519879A (zh) 2015-04-15
KR20150035983A (ko) 2015-04-07

Similar Documents

Publication Publication Date Title
BR112014030279A2 (pt) métodos para tratamento de neutropenia usando agonistas retinóide
BR112015027282A2 (pt) fenfluramina para uso no tratamento de síndrome de dravet
BR112017005693A2 (pt) método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica.
BR112015021371A2 (pt) uso de agonistas de receptor de formil peptídeo 2 para tratar doenças inflamatórias oculares
ZA202208792B (en) Methods of treating and preventing graft versus host disease
BR112016014481A2 (pt) tratamento de câncer utilizando combinações de inibidores de erk e raf
BR112017011536A2 (pt) terapias de combinação
BR112017007072A2 (pt) compostos de triazolopiridina e métodos para o tratamento de fibrose cística
BR112016009889A2 (pt) ?compostos agonistas duplos gip-glp-1 e métodos?
MX2016007351A (es) Terapia de combinacion para tratar cancer.
BR112012031163A2 (pt) métodos de terapia combinada para tratamento de doenças proliferativas
BR112015022047A2 (pt) métodos para tratar câncer de bexiga
BR112014028017A2 (pt) composto, composição farmacêutica, método para tratar um distúrbio, método para reduzir a quantidade il-17 em um indivíduo e método para inibir a atividade de ror
BR112017000301A2 (pt) tratamento de leucemia com inibidores de histona desacetilase
AR101312A1 (es) Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton
UY32989A (es) Coposiciones terapéuticas concentradas de fosfolípidos
BR112014005358A2 (pt) composição para alívio da dor, compreendendo um agonista seletivo de trpv1, e a sua fabricação e utilização
BR112014006220A2 (pt) composições de galacto-ramnogalacturonato para o tratamento de esteatohepatite não alcoólica e de doença de gordura no fígado não alcoólica
BR112014009785A8 (pt) método para tratar ou reduzir efp
BR112015026238A2 (pt) tratamento de câncer com dihidropirazino-pirazinas
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
EA201400002A1 (ru) Способы лечения заболеваний сетчатки
MX2015012547A (es) Tratamiento de una disfuncion cardiaca diastolica con un agonista del receptor trpv2.
BR112014019399A2 (pt) métodos de tratamento da fibrose
MD20160007A2 (ro) Inhibitori ai RORC2 şi metode de utilizare a acestora

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]